| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 59651-0204-10 | 59651-0204 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Apr 17, 2018 | In Use | |
| 00173-0915-61 | 00173-0915 | Niraparib | ZEJULA | 300.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jun 27, 2023 | In Use | |
| 72579-0122-01 | 72579-0122 | Zanubrutinib | BRUKINSA | 160.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Aug 18, 2025 | In Use | |
| 70710-1610-06 | 70710-1610 | Arsenic trioxide | Arsenic trioxide | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Sep 3, 2019 | In Use | |
| 00069-2299-30 | 00069-2299 | dacomitinib | Vizimpro | 45.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Oct 4, 2018 | In Use | |
| 60505-3801-07 | 60505-3801 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 25, 2025 | In Use | |
| 00024-5841-01 | 00024-5841 | ziv-Aflibercept | Zaltrap | 200.0 mg/8mL, 200.0 mg/8mL | Chemotherapy | Recombinant Fusion Protein | VEGF-IgG1 | Intravenous | Aug 3, 2012 | In Use | |
| 00002-6216-54 | 00002-6216 | Abemaciclib | Verzenio | 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct 6, 2017 | In Use | |
| 67457-0425-51 | 67457-0425 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Apr 19, 2012 | Dec 31, 2017 | No Longer Used |
| 54868-5759-00 | 54868-5759 | Dasatinib | Sprycel | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 12, 2007 | In Use | |
| 70121-1221-01 | 70121-1221 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan 19, 2018 | In Use | |
| 63323-0117-59 | 63323-0117 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 12, 2000 | In Use | |
| 00173-0752-00 | 00173-0752 | Lapatinib | TYKERB | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Mar 16, 2007 | Nov 30, 2017 | No Longer Used |
| 00781-3531-91 | 00781-3531 | Paclitaxel | Paclitaxel | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 9, 2024 | In Use | |
| 62332-0622-50 | 62332-0622 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 20, 2022 | In Use | |
| 62332-0567-30 | 62332-0567 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
| 46014-1195-03 | 46014-1195 | talazoparib | Talzenna | 1.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct 26, 2018 | In Use | |
| 63323-0145-07 | 63323-0145 | Floxuridine | Floxuridine | 500.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intra-arterial | Mar 15, 2001 | In Use | |
| 58181-4351-04 | 58181-4351 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 1, 2025 | In Use | |
| 60505-6115-02 | 60505-6115 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Mar 20, 2018 | Jan 31, 2021 | No Longer Used |
| 83831-0131-01 | 83831-0131 | Pemetrexed | AXTLE | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jan 1, 2025 | In Use | |
| 50419-0171-03 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sep 27, 2012 | In Use | |
| 59137-0365-01 | 59137-0365 | Treosulfan | GRAFAPEX | 5000.0 mg/5g | Chemotherapy | Alkylating Agent | Alkyl Sulfonate | Intravenous | Jan 28, 2025 | In Use | |
| 46708-0678-08 | 46708-0678 | Docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb 28, 2023 | In Use | |
| 62756-0826-40 | 62756-0826 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb 20, 2012 | In Use |
Found 12159 results — Export these results
Home